List of Excipients in Branded Drug ZMAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	ZMAX	azithromycin	21695-444	GLYCERYL BEHENATE
Rebel Distributors Corp	ZMAX	azithromycin	21695-444	HYDROXYPROPYL CELLULOSE
Rebel Distributors Corp	ZMAX	azithromycin	21695-444	MAGNESIUM HYDROXIDE
Rebel Distributors Corp	ZMAX	azithromycin	21695-444	POLOXAMER 407
Rebel Distributors Corp	ZMAX	azithromycin	21695-444	SILICON DIOXIDE
Rebel Distributors Corp	ZMAX	azithromycin	21695-444	SODIUM PHOSPHATE, TRIBASIC ANHYDROUS
Rebel Distributors Corp	ZMAX	azithromycin	21695-444	SUCROSE

ZMAX Excipient Strategy and Commercial Opportunities for Azithromycin Extended-Release Suspension

Last updated: August 22, 2026

ZMAX is an azithromycin extended-release oral suspension designed to deliver a 2-gram dose in a single administration. Its commercial differentiation depended less on the active ingredient than on excipient-enabled taste masking, controlled release, reconstitution performance, dose uniformity, and treatment convenience. The strongest opportunities today are follow-on products, pediatric and adult taste-masked azithromycin suspensions, ready-to-use presentations, and reformulations that improve gastrointestinal tolerability and supply-chain economics.

What is ZMAX and how does its formulation work?

ZMAX is an extended-release formulation of azithromycin supplied as a powder for oral suspension. The product was developed to provide single-dose administration through a multiparticulate delivery system rather than conventional immediate-release azithromycin tablets or suspensions.

The historical U.S. product was approved under NDA 050797. The labeled dosage was a single 2-gram oral dose after reconstitution, with administration requirements designed to limit food-related variability and preserve product performance. The formulation used azithromycin extended-release microspheres dispersed in a powder matrix for reconstitution [1].

What commercial problem did ZMAX solve?

ZMAX addressed four limitations of conventional azithromycin products:

Commercial problem	ZMAX formulation response
Multi-day dosing	Single 2-gram administration
Poor taste of macrolide suspensions	Taste-masking excipient system and multiparticulate design
High liquid-shipping cost	Dry powder presentation before reconstitution
Adherence risk	Reduced dosing frequency

The formulation also created a proprietary delivery profile. A conventional azithromycin suspension releases the drug rapidly, while ZMAX was designed to delay and extend release to improve tolerability and support single-dose treatment [1].

What excipients were used in the ZMAX formulation?

The ZMAX formulation included excipients associated with microsphere manufacture, suspension stability, powder flow, reconstitution, taste management, and physical appearance. The FDA-approved labeling identifies inactive ingredients including sucrose, glyceryl behenate, poloxamer 407, anhydrous tribasic sodium phosphate, colloidal silicon dioxide, xanthan gum, and titanium dioxide, subject to product-specific labeling versions [1].

Because formulation composition can vary by manufacturing site and label revision, the FDA-approved product label and inactive-ingredient records are the controlling sources for regulatory work. The key excipient functions are clear:

Excipient or excipient class	Primary formulation role	Commercial relevance
Sucrose	Bulking agent, taste contribution, powder matrix	Supports palatability and dose presentation
Glyceryl behenate	Lipid matrix former and release-modifying excipient	Supports extended release in microspheres
Poloxamer 407	Wetting, dispersion, and processing aid	Helps reconstitution and particulate dispersion
Tribasic sodium phosphate	Buffering and pH control	Supports chemical and physical stability
Colloidal silicon dioxide	Glidant and flow aid	Improves powder handling and filling
Xanthan gum	Suspending and rheology-control agent	Reduces settling after reconstitution
Titanium dioxide	Opacifier and appearance modifier	Supports product identity and visual uniformity

Why is glyceryl behenate strategically important?

Glyceryl behenate is likely the most commercially significant excipient in the ZMAX platform because it supports lipid-based matrix formation around azithromycin particles. Its concentration, particle size, melting behavior, and processing conditions affect:

• Drug release rate.
• Microsphere morphology.
• Batch-to-batch content uniformity.
• Reconstitution behavior.
• Residual taste perception.
• Manufacturing yield.

A follow-on manufacturer cannot treat glyceryl behenate as a simple filler substitution. Changes in grade, supplier, or thermal processing can alter the release profile and may trigger additional formulation development or regulatory bridging.

What role does xanthan gum play?

Xanthan gum controls the viscosity of the reconstituted suspension. The target is a balance between sedimentation control and pourability. Excessive viscosity can impair dosing, increase residual volume in the bottle, and create poor patient acceptance. Insufficient viscosity can cause rapid settling and dose nonuniformity.

For a single-dose product, the required suspension-use period is shorter than for a 10-day antibiotic suspension. That creates room to optimize xanthan gum concentration for rapid redispersion rather than long-term suspension stability.

How does ZMAX compare with conventional azithromycin formulations?

ZMAX competes with immediate-release azithromycin tablets, capsules, and oral suspensions. Its formulation advantage is dose reduction, but its disadvantages include a higher active-ingredient load, greater taste-masking burden, more complex manufacturing, and potential gastrointestinal adverse effects.

Attribute	ZMAX	Immediate-release azithromycin suspension	Azithromycin tablets
Dosage form	Extended-release suspension	Immediate-release suspension	Immediate-release solid oral
Typical dosing concept	Single 2-gram dose	Multi-day regimen	Multi-day regimen
Main excipient challenge	Microsphere release plus palatability	Taste and suspension stability	Tablet disintegration and coating
Manufacturing complexity	High	Moderate	Moderate
Pediatric suitability	Potentially attractive, but taste-sensitive	Established pediatric use	Limited by swallowing ability
Supply-chain burden	Dry powder; reconstituted at dispensing	Dry powder or liquid	Low
Differentiation	Adherence and convenience	Familiarity and lower formulation complexity	Low cost and broad availability

The major commercial weakness of ZMAX is that the 2-gram dose increases the importance of taste masking and gastrointestinal tolerability. A follow-on product that retains single-dose convenience while reducing perceived nausea, bitterness, or chalkiness could compete more effectively than a product that merely duplicates the original excipient list.

What formulation patents protect ZMAX?

ZMAX protection historically centered on the extended-release azithromycin microsphere formulation, manufacturing process, and dosage form rather than on azithromycin itself. Azithromycin was an established active pharmaceutical ingredient, so product differentiation depended on formulation and delivery technology.

The principal patent categories were:

1. Azithromycin extended-release microspheres.
2. Lipid or polymeric matrix systems.
3. Powder-for-reconstitution presentations.
4. Single-dose administration methods.
5. Manufacturing processes for controlled-release particles.

A historically associated U.S. patent is U.S. Patent No. 6,068,859, directed to azithromycin pharmaceutical compositions and extended-release technology. Its original term would have placed expiration in the late 2010s, subject to patent-term adjustment, patent-term extension, and claim-specific scope. Current freedom-to-operate analysis must distinguish expired composition claims from any later patents covering manufacturing, crystalline forms, packaging, or specific excipient combinations.

When did ZMAX lose exclusivity?

ZMAX’s core small-molecule and formulation exclusivity periods are historical rather than biologic exclusivity periods. The product was approved in 2005, and any five-year new chemical entity exclusivity would have expired before the end of the 2000s. Later market protection depended on formulation patents, regulatory exclusivity, and litigation outcomes rather than on azithromycin’s underlying active-ingredient patent estate.

No biosimilar pathway applies. Azithromycin is a small molecule, so competitive entry would generally proceed through an ANDA, a 505(b)(2) application, or a conventional NDA depending on the proposed product and reliance strategy.

What FDA regulatory pathway applies to a ZMAX follow-on?

A follow-on product could pursue one of three principal routes:

Regulatory route	Product concept	Key burden
ANDA under section 505(j)	Therapeutically equivalent generic extended-release suspension	Demonstration of pharmaceutical equivalence, bioequivalence, and quality
505(b)(2) NDA	Reformulated or improved extended-release azithromycin	Partial reliance on prior findings plus bridging studies
Full NDA	Materially different delivery system or new clinical claim	Complete development package

The ANDA route is commercially attractive if the applicant can match the reference product’s active ingredient, dosage form, strength, release characteristics, labeling, and bioequivalence requirements. A materially different microsphere system, flavor architecture, preservative system, or ready-to-use liquid could push the product toward 505(b)(2).

FDA guidance for orally administered extended-release products emphasizes the importance of comparative pharmacokinetics, dose proportionality, food effects, and in vitro dissolution testing [2]. A formulation that changes particle size, lipid matrix composition, or release-modifying excipient levels may require a substantial analytical package.

Is ZMAX listed in the Orange Book?

ZMAX was associated with NDA 050797. Orange Book treatment depends on the product’s current marketing status and listed patents. A company evaluating an ANDA must review the current electronic Orange Book entry, patent listings, use codes, and any delisting or expiration information before relying on a paragraph IV strategy [3].

An applicant challenging any unexpired listed patent could file a paragraph IV certification. If the patent holder filed infringement litigation within the statutory period, FDA approval could be subject to a 30-month stay, subject to applicable statutory exceptions and court actions.

What paragraph IV and litigation risks affect ZMAX?

The principal litigation risk for a ZMAX follow-on would arise from formulation patents, not from the basic azithromycin molecule. Potential claim categories include:

• Extended-release microspheres containing azithromycin.
• Specific lipid excipient ratios.
• Particle-size distributions.
• Release profiles.
• Powder-for-suspension compositions.
• Single-dose treatment methods.

What settlement structures would be commercially relevant?

A settlement with the reference sponsor could include:

• A licensed entry date before patent expiration.
• A royalty-bearing license.
• A restriction on specific formulations.
• Authorized-generic supply.
• A commitment not to challenge manufacturing patents.
• A carve-out from a patented method of use.

For a mature antibiotic product, settlement value is usually limited by low expected pricing and multiple alternative azithromycin presentations. Litigation economics improve only if the follow-on product has meaningful channel access, pediatric positioning, or a differentiated delivery profile.

What excipient strategies create the strongest commercial opportunities?

1. Superior taste masking

The 2-gram azithromycin dose creates a high taste burden. Commercially relevant approaches include:

• Ion-exchange resins.
• Lipid coating.
• Polymer film coating.
• Encapsulation of drug-loaded particles.
• Sweetener and flavor systems.
• pH adjustment.
• Reduced-contact multiparticulates.

A taste-masked formulation should be tested against bitterness duration, aftertaste, mouthfeel, and dose volume. A formulation that tastes acceptable initially but leaves a prolonged bitter residue may fail in pediatric or outpatient use.

2. Ready-to-use liquid formulation

A ready-to-use ZMAX-type product could eliminate reconstitution errors and improve pharmacy workflow. The tradeoffs are higher shipping weight, microbial-control requirements, preservative exposure, and shorter shelf life.

The commercial opportunity is strongest in:

• Emergency departments.
• Urgent-care clinics.
• Pediatric outpatient settings.
• Public-health distribution.
• Travel medicine.
• Low-resource environments where reconstitution water quality is variable.

3. Lower-volume presentation

A 2-gram dose can require a substantial powder and liquid volume. Reducing final dose volume without increasing bitterness could improve acceptance and reduce packaging size. This requires high drug loading, efficient microsphere formation, and strong taste masking.

4. Preservative-free single-dose packaging

Because ZMAX is intended for single administration, a preservative-free presentation may be feasible if the product is packaged as a unit dose and used promptly after reconstitution. This could support differentiation for pediatric and preservative-sensitive populations.

5. Excipient simplification

A shorter excipient list can reduce sourcing risk and simplify regulatory justification. Potential targets include:

• Fewer flavors.
• Elimination of titanium dioxide where commercially and regulatorily appropriate.
• Reduced reliance on specialized grades.
• Common pharmacopeial excipients with multiple qualified suppliers.
• Lower sucrose content for specific patient segments.

Excipient reduction must not compromise suspension uniformity, release performance, or palatability.

How strong is the ZMAX patent estate for a new entrant?

The estate is likely weaker against a conventional immediate-release azithromycin product and stronger against a close copy of the original extended-release microsphere system. Core historical patents may be expired, but freedom-to-operate risk can remain in:

• Later process patents.
• Manufacturing know-how.
• Supplier-specific excipient grades.
• Packaging and reconstitution configurations.
• Method-of-use claims.
• Foreign patents with different expiration dates.
• Trade secrets involving microsphere processing.

A new entrant should avoid unnecessary duplication of the original particle architecture. A distinct release platform could reduce infringement risk and support a 505(b)(2) strategy, but it may increase clinical and bioequivalence requirements.

Which companies are challenging or competing with ZMAX?

The competitive field consists primarily of azithromycin generic manufacturers and established antibiotic suppliers rather than direct ZMAX-equivalent competitors. Relevant competitors include companies marketing:

• Azithromycin tablets.
• Azithromycin capsules.
• Immediate-release oral suspensions.
• Intravenous azithromycin.
• Other single-dose or short-course antibacterial therapies.

The most credible commercial challengers are generic manufacturers with existing azithromycin production, analytical infrastructure, and pharmacy distribution. Their advantage is cost. Their weakness is the technical complexity of reproducing a palatable extended-release 2-gram suspension.

What is the revenue opportunity for a ZMAX follow-on?

The opportunity is unlikely to come from premium pricing for azithromycin alone. It would depend on a differentiated product strategy.

Opportunity	Pricing potential	Development risk	Commercial attractiveness
Conventional azithromycin generic	Low	Low	Moderate volume, low margin
Direct ZMAX-equivalent generic	Moderate	High	Dependent on limited competition
Better-tasting pediatric suspension	Moderate to high	Moderate to high	Strong adherence value
Ready-to-use single-dose liquid	Moderate	High	Useful in institutional channels
Preservative-free unit dose	Moderate	Moderate	Niche but defensible
Novel controlled-release platform	High initially	High	Potential 505(b)(2) differentiation

Revenue exposure for the reference product would have been concentrated in outpatient infectious-disease prescriptions, urgent care, pediatric prescribing, and institutional use. Current commercial value depends on market availability, generic competition, resistance trends, and stewardship policies.

What geographic markets are most attractive?

The United States offers the clearest regulatory pathway through ANDA or 505(b)(2), but market access depends on current Orange Book status and reference-product availability.

Other markets may offer opportunities for:

• Pediatric taste-masked suspensions.
• Single-dose treatment in outpatient clinics.
• Dry powder products where cold-chain-free distribution is important.
• Public-sector procurement.
• Hospital discharge packs.
• Tropical and rural settings with limited pharmacy infrastructure.

Excipients must be reviewed against local restrictions, including permitted colorants, titanium dioxide requirements, sucrose labeling, preservative standards, and pediatric-use expectations.

What manufacturing and IP barriers matter most?

The main technical barrier is not azithromycin synthesis. It is reproducible manufacture of drug-loaded particles with controlled release and acceptable taste.

Critical process parameters include:

• Drug-to-lipid ratio.
• Melt or solvent-processing temperature.
• Particle-size distribution.
• Encapsulation efficiency.
• Surface drug level.
• Mixing energy.
• Powder bulk density.
• Reconstitution time.
• Dissolution profile.
• Moisture exposure.

Critical quality attributes include assay, content uniformity, dissolution, particle morphology, microbial quality, sedimentation, redispersibility, and palatability.

The most defensible commercial position would combine a non-infringing particle platform with a proprietary excipient system and reliable low-cost manufacturing. Trade-secret protection could remain important even where historical patents have expired.

Key Takeaways

• ZMAX’s commercial differentiation came from single-dose azithromycin delivery enabled by an extended-release microsphere formulation.
• Glyceryl behenate, poloxamer 407, xanthan gum, sucrose, buffering agents, and flow aids each support distinct performance requirements.
• The highest-value excipient opportunity is improved taste masking for the 2-gram dose.
• A direct follow-on may require complex bioequivalence and dissolution studies because release behavior depends on particle architecture and excipient processing.
• A conventional azithromycin generic has lower technical risk but limited pricing power.
• Ready-to-use, preservative-free, low-volume, and pediatric-focused products offer stronger differentiation.
• ZMAX has no biosimilar pathway. Competition would proceed through an ANDA, 505(b)(2), or full NDA.
• Historical patent protection focused on extended-release compositions and manufacturing technology rather than the azithromycin molecule.
• Current Orange Book listings, patent certifications, and litigation exposure should control any launch-timing decision.
• The strongest entrant strategy is a differentiated, palatable, single-dose formulation supported by scalable microsphere manufacturing.

FAQs About ZMAX Excipients and Commercial Strategy

Can a generic manufacturer replace glyceryl behenate in a ZMAX-type formulation?

Yes, but substitution can materially change drug release, particle morphology, dissolution, and taste. The replacement would require comparative formulation and regulatory justification.

Is ZMAX suitable for pediatric drug development?

The single-dose concept is attractive for pediatrics, but the 2-gram azithromycin load creates major palatability and gastrointestinal-tolerability challenges. Pediatric positioning would require age-appropriate dosing, taste studies, and careful volume control.

Could a ZMAX follow-on use a different flavor system?

Yes. Flavor changes are generally feasible, but they must be evaluated with sweetness, bitterness suppression, aftertaste, preservative compatibility, and stability testing.

Would a ready-to-use ZMAX liquid need a new clinical study?

Potentially. A ready-to-use product that changes excipients, concentration, release behavior, or administration conditions may require additional comparative pharmacokinetic, stability, microbiological, and clinical data under the selected FDA pathway.

Is azithromycin resistance a commercial risk for ZMAX-type products?

Yes. Antimicrobial stewardship, local resistance patterns, treatment guidelines, and payer policies can reduce demand even when the formulation has strong adherence advantages.

References

1. U.S. Food and Drug Administration. (2005). ZMAX (azithromycin) extended-release oral suspension prescribing information. Pfizer Inc.

2. U.S. Food and Drug Administration. (2015). Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Electronic Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

5. U.S. Patent No. 6,068,859. (2000). Azithromycin pharmaceutical compositions. U.S. Patent and Trademark Office.